IRCT20200623047902N1招募中未知
Bioequivalence study and evaluation of pharmacokinetic parameters of Dimethyl fumarate medicine manufactured by Zistdaru danesh company (Teczifuma 240) versus Tecfidera 240 manufactured by Biogen Company (originator brand) in healthy volunteers
Zistdaru danesh Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart and Kidney), Body Mass Index (18-28), Conscious Consciousness, Age (18-60)
排除标准
- •Smoking, history of cardiovascular disease, history of liver and kidney disease, pregnancy, alcohol and drug addiction, history of drug allergy
研究者
相似试验
未知
1 期
DMB-3111 phase IHealthy volunteersJPRN-jRCT2080222436Meiji Seika Pharma Co., Ltd.70
已完成
1 期
Bioequivalence (BE) study of a new branded generic of Etoricoxib (ETO) tabletEtoricoxib could commonly cause edema, dizziness, headache, palpitations, arrhythmia, hypertension, bronchospasm, constipation, heartburn and gastritis.Bioequivalence studyEtoricoxibgenericsTCTR20210714009/A24
未知
1 期
DMB-3113 Phase IJPRN-jRCT2080223335Meiji Seika Pharma Co., Ltd.180
已完成
不适用
Bioequivalence (BE) Study of a New Branded Generic of Moxifloxacin TabletsMoxifloxacin could potentially cause nausea,diarrhea,headache,vomiting,dizziness,nervousness,agitation and nightmares. As for the safety of the formulation,no adverse event was reported based oMoxifloxacinbioequivalencepharmacokineticsTCTR20201109001/A30
暂停
不适用
Bioequivalence Study Comparing Generic to Reference Liposome-Encapsulated Doxorubicin HydrochlorideCTRI/2019/05/019051Aine Cunningham